Information Provided By:
Fly News Breaks for May 3, 2018
STAA
May 3, 2018 | 07:27 EDT
As previously reported, Stephens analyst Chris Cooley upgraded STAAR Surgical to Overweight from Equal Weight after the company reported above consensus Q1 results and increased its 2018 revenue growth guidance. The FDA commenced a re-inspection STAAR's Monrovia facility on April 30, which is "of equal if not greater importance" as it means a favorable resolution of the Warning Letter is now potentially possible nearer-term, Cooley tells investors. He raised his price target on STAAR shares to $21 from $13.
News For STAA From the Last 2 Days
There are no results for your query STAA